Ocugen begins Phase III trial of OCU410 gene therapy for GA

Phase 3OCU410Positive

AI Analysis

Summary

Ocugen has initiated its global Phase III ArMaDa3 trial of OCU410, a gene therapy for geographic atrophy secondary to dry age-related macular degeneration, with enrollment of the first patient. The trial represents progression of the investigational therapy toward potential regulatory approval.

Clinical Trial Data

Phase

III

Importance:6/10

Sentiment:

0.30

gene therapyPhase 3geographic atrophyOCU410ArMaDa3 trial

Related Companies

$GBCYD $TRAX $ARNA

Read the original article

Published by Clinical Trials Arena on September 2, 2026 9:36 AM

Read Original